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Abstract
Mitochondria play a central role in cellular energy provision. The organelles contain their own genome with a modified
genetic code. The mammalian mitochondrial genome is transmitted exclusively through the female germ line. The human
mitochondrial DNA (mtDNA) is a double-stranded, circular molecule of 16 569 bp and contains 37 genes coding for two
rRNAs, 22 tRNAs and 13 polypeptides. The mtDNA-encoded polypeptides are all subunits of enzyme complexes of the
oxidative phosphorylation system. Mitochondria are not self-supporting entities but rely heavily for their functions on
imported nuclear gene products. The basic mechanisms of mitochondrial gene expression have been solved. Cis-acting
mtDNA sequences have been characterised by sequence comparisons, mapping studies and mutation analysis both in vitro
and in patients harbouring mtDNA mutations. Characterisation of trans-acting factors has proven more difficult but several
key enzymes involved in mtDNA replication, transcription and protein synthesis have now been biochemically identified and
some have been cloned. These studies revealed that, although some factors may have an additional function elsewhere in the
cell, most are unique to mitochondria. It is expected that cell cultures of patients with mitochondrial diseases will increasingly
be used to address fundamental questions about mtDNA expression. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mitochondria are the energy-transducing organ-
elles of eukaryotic cells in which fuels to drive cellu-
lar metabolism are converted into ATP through the
process of oxidative phosphorylation. Mitochondria
have a double membrane. The outer membrane sep-
arates the mitochondrion from the cytosol. The inner
membrane is invaginated to form the cristae which
protrude into and de¢ne the matrix of the organelle.
The ¢ve enzyme complexes of the oxidative phos-
phorylation system [1] are embedded in the mito-
chondrial inner membrane. Mitochondria contain
their own genome, the mitochondrial DNA
(mtDNA), which is located in the mitochondrial ma-
trix. In mammalian cells, each organelle generally
contains several identical copies of mtDNA [2^5].
Mitochondria are thought to have originated from
incorporated K-purple bacteria [6]. During its evolu-
tion into the present-day powerhouses of the eukary-
otic cell, the endosymbiont transferred many of its
essential genes to the nuclear chromosomes. Never-
theless, the mitochondrion still carries hallmarks of
its bacterial ancestor. For instance, mitochondria use
an N-formylmethionyl-tRNA (fMet-tRNA) as initia-
tor of protein synthesis [7,8].
For over 20 years, it has been recognised that, in
mammals, mtDNA is only transmitted through the
female germ line [9^12]. In mammalian sperm cells,
the copy number of mtDNA is low (50^75 [13]),
whereas in mammalian oocytes the copy number is
extremely high (v 105 [2,14]). Therefore, the mater-
nal inheritance of mtDNA observed in early studies
could simply have been the result of dilution of the
paternal contribution beyond the detection limit of
the restriction enzyme analysis on which these studies
relied. In a more recent investigation, in which a
more sensitive, PCR-based technique was used, low
levels of paternal mtDNA were detected in interspe-
ci¢c hybrids of the mice species Mus musculus and
Mus spretus throughout development from pronu-
cleus stage to neonates [15]. In intraspeci¢c o¡spring
of M. musculus, however, paternal mtDNA was only
detected in the early pronucleus stage [15]. In the
majority of mammals, including humans, sperm mi-
tochondria are transferred to the oocyte during fer-
tilisation [16], but detailed morphological studies in
rodents [15,17] and cows [18] have indicated that
sperm-derived mitochondria are lost early in embryo-
genesis. The mechanism underlying the elimination
of sperm-derived mitochondria is unknown but the
leakage of paternal mtDNA in progenies of interspe-
ci¢c mice crosses suggest that this process is species
speci¢c. Although it is not clear to which extent the
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observations in rodents and cows can be extrapo-
lated to the human oocyte [16], Manfredi and col-
leagues [19] recently showed that re-population of
experimental human somatic cells lacking endoge-
nous mtDNA (b0 cells) by mtDNA can occur after
entry of human sperm but is an extremely rare event.
This review focuses on human mtDNA. Some as-
pects of the expression of human mtDNA, however,
are still poorly characterised. In those cases, our cur-
rent understanding of the situation in other eukar-
yotes will be discussed.
2. Structure of mtDNA
As mtDNA is a relatively small, abundant and
easy to isolate DNA molecule, it has been the fa-
vourite target of early genome sequencing projects
and the nucleotide sequence of mtDNA from a large
number of species has now been determined [20]. The
nucleotide sequence of the human mtDNA was the
¢rst documented complete sequence of a mitochon-
drial genome [21]. Structure and gene organisation of
mtDNA is highly conserved among mammals [22].
The mammalian mitochondrial genome is a closed-
circular, double-stranded DNA molecule of about
16.6 kb. The strands of the DNA duplex can be
distinguished on the basis of G+T base composition
which results in di¡erent buoyant densities of each
strand (‘heavy’ and ‘light’) in denaturing caesium
chloride gradients [23]. Most information is encoded
on the heavy (H) strand, with genes for two rRNAs,
14 tRNAs, and 12 polypeptides. The light (L) strand
codes for eight tRNAs and a single polypeptide. All
13 protein products are constituents of the enzyme
complexes of the oxidative phosphorylation system
[21,24^26]. Mammalian mtDNA displays exceptional
economy of organisation. The genes lack introns
and, except for one regulatory region, intergenetic
sequences are absent or limited to a few bases.
Both rRNA and tRNA molecules are unusually
small [22]. Some of the protein genes are overlapping
and, in many cases, part of the termination codons
are not encoded but are generated post-transcription-
ally by polyadenylation of the mRNAs [27]. A map
of the human mtDNA is given in Fig. 1.
Soon after mtDNA sequences became available,
comparisons with mitochondrial protein sequences
revealed deviations from the standard genetic code
and later even variations in codon usage were found
in mitochondria from di¡erent species (summarised
in [28]). For instance, in mtDNA of most phyloge-
netic groups, TGA is used as a tryptophan codon,
rather than as a termination codon. On the other
hand, AGR (R = A, G) speci¢es a stop in mtDNA
of vertebrates, codes for serine in mtDNA of echino-
derms and codes for arginine in mtDNA of yeast, as
in the standard genetic code.
Another surprising feature of the mitochondrial
genetic system is its use of a simpli¢ed decoding
Fig. 1. Map of the human mitochondrial genome (16 569 bp).
The outer circle represents the H-strand, containing the major-
ity of the genes; the inner circle represents the L-strand. The
D-loop is shown as a three-stranded structure. The origins of
H-strand (OH) and L-strand (OL) replication and the direction
of DNA synthesis are indicated by long bent arrows; the initia-
tion of transcription sites (ITL, ITH1, ITH2) and the direction of
RNA synthesis are denoted by short bent arrows. The binding
site for the mitochondrial transcription terminator (mtTERM)
is indicated. The 22 tRNA genes are depicted by dots and the
single letter code of the amino acid (isoacceptors for serine and
leucine are distinguished by their codon sequence). The genes
coding for the two rRNA species (12S and 16S) and the 13
protein coding genes are depicted by shaded boxes. ND, CO
and ATPase refer to genes coding for subunits of NADH:
ubiquinone oxidoreductase, ferrocytochrome c :oxygen oxidore-
ductase (cytochrome c oxidase) and F1F0-ATP synthase, respec-
tively, whereas Cyt b encodes apocytochrome b of ubiquinol:
ferricytochrome c oxidoreductase.
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mechanism, allowing translation of all codons with
less than the 32 tRNA species required according to
Crick’s wobble hypothesis. This reduction in the
number of tRNA species is achieved by the use of
a single tRNA with U in the ¢rst anticodon (wobble)
position to recognise all codons of a four-codon fam-
ily [29,30]. Fungal mitochondria use a modi¢ed U in
the wobble position to read two codon families with
a purine in the third position of the codon [31,32].
This mechanism prevents misreading of two codon
families with a pyrimidine in the third position and is
considered to be conserved in vertebrate mitochon-
dria. This would imply that 24 tRNA species are
required to decode mtDNA, however, as mentioned
above, in vertebrates AGR codons indicate a stop
and the corresponding tRNA gene is absent. Fur-
thermore, a single tRNA species, with a modi¢ed C
in the ¢rst anticodon position followed by AU, func-
tions for initiation (tRNAfMet) as well as elongation
(tRNAMet) and pairs with codon AUA in addition to
AUG [28,33]. Hence, the 22 tRNA species encoded
by human mtDNA are su⁄cient to translate all 13
mitochondrial protein genes.
In vertebrate cells that are metabolically active, a
large proportion of the mtDNA duplexes contain a
short three-stranded structure, called the displace-
ment loop or D-loop [23], in which a short nucleic
acid strand, complementary to the L-strand, displa-
ces the H-strand. The D-loop region is bounded by
the genes for tRNAPhe and tRNAPro [34] and has
evolved as the major control site for mtDNA expres-
sion, containing the leading-strand origin of replica-
tion and the major promoters for transcription (Fig.
1).
Mitochondria are not self-supporting entities in
the cell. Replication and transcription depend upon
trans-acting nuclear-encoded factors. Mitochondrial
tRNAs are charged by imported aminoacyl-tRNA
synthases and, in vertebrates, all mitochondrial ribo-
somal proteins are coded and synthesised outside the
organelle. Enzymes of the various catabolytic path-
ways located in the mitochondria, as well as the com-
ponents of the mitochondrial import machinery, are
encoded by nuclear DNA. Even the enzyme com-
plexes of the oxidative phosphorylation system are
of hybrid genetic origin. All nuclear-encoded poly-
peptides destined for mitochondria are synthesised
on cytosolic ribosomes, usually with a cleavable, N-
terminal presequence for mitochondrial targeting and
are subsequently imported into mitochondria (re-
viewed in [35]).
3. Transcription of mtDNA
3.1. Initiation of transcription
The basic mechanism of mitochondrial transcrip-
tion has been solved in representative species of sev-
eral phylogenetic groups (reviewed in [36^38]). Hu-
man mtDNA transcription initiation sites and
promoter regions have been determined using a vari-
ety of techniques, including 5P-end mapping of pri-
mary mitochondrial transcripts by S1 nuclease pro-
tection experiments [39^41] and deletion [42^44], site-
directed mutagenesis [45] and linker substitution
analyses [46] of cloned mtDNA fragments in run-
o¡ transcription assays. All available data are
consistent with the conclusion that there are two
major transcription initiation sites in the D-loop
(ITH1 and ITL) situated within 150 bp of one another
(Fig. 2). A promoter element with a 15-bp consensus
sequence motif, 5P-CANACC(G)CC(A)AAAGAYA,
surrounds the transcription initiation sites (under-
lined) and is critical for transcription [43,45].
H-strand transcription starts at nucleotide position
561 (ITH1 ; numbering according to [21]) located
within the H-strand promoter (HSP) and immedi-
ately adjacent to the tRNAPhe gene, whereas the
L-strand transcription starts at nucleotide position
407 (ITL) located within the L-strand promoter
(LSP). Additional upstream enhancer elements are
required for optimal transcription (Fig. 2). These el-
ements, which were later shown to include binding
sites for a transcription factor (mtTFA, see below),
exhibit sequence similarity but only if one element is
inverted relative to the other [43,45,47].
Despite the close proximity of the HSP and LSP,
the initial in vitro transcription studies demonstrated
that these elements are functionally independent
[42,43,45,46]. This functional autonomy was later
corroborated in patients with progressive external
ophthalmoplegia, harbouring a large-scale deletion,
including the HSP, in a sub-population of their
mtDNA molecules. In situ hybridisation experiments
revealed focal accumulations of deleted mtDNA
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and L-strand transcripts with concomitant depletion
of H-strand transcripts in muscle ¢bres of the pa-
tients [48,49]. These results con¢rm the functional
independence of the transcriptional promoters in
vivo.
A second putative initiation site for H-strand tran-
scription is located around nucleotide position 638
(ITH2) in the tRNAPhe gene, immediately adjacent
to the gene for 12S rRNA (Fig. 2). Its promoter
region only shows limited similarity with the 15-bp
consensus sequence and this site is used less fre-
quently than ITH1 for transcription of the H-strand
[39^41,43].
Although there is a fairly detailed picture of the
cis-acting elements involved in mtDNA transcrip-
tion, knowledge of the trans-acting nuclear-encoded
factors is still incomplete. Biophysical fractionation
of human mitochondrial transcription extracts have
revealed the requirement of at least two trans-acting
proteins: a relatively non-selective core RNA po-
lymerase and a dissociable transcription factor which
confers promoter selectivity on the polymerase
[47,50]. The core enzyme is expected to interact
with the HSP and LSP as mutations in these do-
mains obliterate even the lowest level of transcription
[46]. Mitochondrial RNA polymerases have not been
puri¢ed to homogeneity. Nevertheless, human cDNA
specifying mitochondrial RNA polymerase was re-
cently identi¢ed by screening of an expressed se-
quence tags (EST) database with the yeast sequence
[51]. Interestingly, the C-terminal half of the pre-
dicted polypeptide shares signi¢cant amino acid se-
quence identity with the single subunit RNA polym-
erases of T3, T7 and SP6 bacteriophages.
The human dissociable transcription factor acting
in concert with the core mitochondrial RNA polym-
erase has been puri¢ed [52,53], its cDNA has been
cloned and sequenced [54] and its gene has been
characterised [55^57]. The factor, now termed
mtTFA [58], is an abundant 25-kDa mitochondrial
protein and is largely comprised of two high mobility
group (HMG) domains separated by a 27-amino acid
residue linker and followed by a 25-amino acid res-
idue basic C-terminal tail. HMG domains are con-
sidered to be involved in DNA binding and are
found in a rather diverse family of proteins whose
members have been implicated in processes such as
transcription enhancement and chromatin packaging
Fig. 2. Schematic representation of the initiation of transcription and replication of human mtDNA. The genes encoding 12S rRNA,
tRNAPhe and tRNAPro are indicated with boxes on the H- and L-strands. Transcription initiation sites and direction of synthesis are
indicated by bent arrows, dotted lines represent synthesised RNA. In the D-loop region (the 1118-bp sequence between nucleotides
577 and 16028), two major transcription initiation sites are present. Transcription initiation site ITH1, encompassed by the H-strand
promoter (HSP), directs the transcription of the H-strand, whereas transcription initiation site ITL, encompassed by the L-strand pro-
moter (LSP), directs the transcription of the L-strand. A second, minor transcription initiation site (ITH2) for H-strand transcription
is located in the gene for tRNAPhe near the boundary with the 12S rRNA gene. Enhancer elements upstream of the HSP and LSP
that are known to bind the mitochondrial transcription factor mtTFA are indicated. A short (RNA) transcript originating at ITL
serves as a primer for replication of the (leading) H-strand. Transitions from RNA to DNA occur within the dashed line, in the re-
gion around the conserved sequence blocks (CSBs) I, II and III. OH is the origin of H-strand synthesis. Short DNA strands that are
part of the triplex D-loop structure terminate near the termination-associated sequence (TAS).
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[59]. Mutation analysis of the human mtTFA has
demonstrated that its C-terminal tail is important
for speci¢c DNA recognition and is essential for
sponsoring of high levels of speci¢c initiation of tran-
scription [60].
In vitro DNase I protection studies in combination
with run-o¡ transcription assays have demonstrated
that binding of mtTFA to regions immediately up-
stream of the HSP or LSP (10^40 bp upstream of
each start site) is required for speci¢c initiation of
transcription [46,47,52,53]. Binding of mtTFA at
these regions was recently supported by in organello
footprinting experiments [61,62]. Both major tran-
scription promoters in human mitochondria can
function bidirectionally, in vitro as well as in vivo
[63]. The asymmetric binding of mtTFA relative to
the transcription start site may ensure that transcrip-
tion proceeds primarily in an unidirectional fashion
(Fig. 2). There is a strict requirement for the natural
10-bp spacing (one helical turn) between the mtTFA
binding site and the start site of transcription [64].
The transcription factor has the ability to wrap and
unwind DNA in vitro in an essentially non-speci¢c
protein-DNA complex [65,66] and scanning trans-
mission electron microscopy recently revealed that
the Xenopus homologue causes sharp bending of
the DNA duplex at the promoter activation site
[67]. These mtTFA-induced conformational changes
of mtDNA may be required to allow the core RNA
polymerase access to the template for initiation of
the transcription process.
DNase footprinting and transcription studies have
indicated that the a⁄nity of mtTFA for its binding
site immediately upstream of the LSP is relatively
strong and that mtTFA markedly enhances L-strand
transcription. Conversely, the a⁄nity for its binding
site upstream of the HSP is several fold weaker and
mtTFA only moderately stimulates H-strand tran-
scription [47,52,53,61]. This suggests that additional
factors, not operating in the in vitro system may be
necessary for e¡ective transcription initiation at the
HSP in vivo. As mammalian mitochondrial RNA
polymerase has not been puri¢ed to homogeneity,
other accessory proteins may be present in the active
mitochondrial RNA polymerase fractions. Although
there is no direct evidence for any mammalian sup-
plementary components at the present time, an addi-
tional 40-kDa protein, obligatory for promoter-
directed transcription selectivity of the core mito-
chondrial RNA polymerase, has been identi¢ed in
several yeast species [68^70] and Xenopus laevis
[71,72]. This factor, designated mtTFB, exhibits se-
quence homology to the dissociable c subunit of
bacterial RNA polymerases [69] which is responsible
for promoter recognition of the bacterial holo-en-
zyme.
3.2. Elongation and termination of transcription
Once initiated at the LSP, the L-strand is tran-
scribed as a single polycistronic precursor RNA, en-
compassing most, if not all, genetic information po-
tentially encoded on the strand [73,74]. Although the
HSP may direct transcription of the entire H-strand
in a similar fashion, a more complicated model has
been postulated by Attardi and colleagues [40]. In
exponentially growing HeLa cells, the rRNAs are
synthesised at a much higher rate than the individual
mRNAs encoded on the H-strand [75]. This di¡er-
ence has been explained in part by the existence in
vivo of two distinct initiation sites (ITH1 and ITH2 ;
Fig. 2) for H-strand transcription [39]. According to
the dual H-strand transcription model, transcription
starts relatively frequent at the ITH1 and then termi-
nates at the downstream end of the 16S rRNA gene.
This transcription process is responsible for synthesis
of the vast majority of the two rRNA species. In
contrast, transcription starting at ITH2 is less fre-
quent but results in polycistronic molecules corre-
sponding to almost the entire H-strand, yielding all
the mRNAs and most of the tRNAs encoded on the
H-strand. Evidence for two independently controlled,
overlapping transcription units is supported by the
observation, both in vivo and in isolated mitochon-
dria, of two types of transcripts of the ribosomal
genes with di¡erent kinetic properties [40]. Consis-
tent with this model, Attardi’s group found that
the relative transcription rates of rRNA and
mRNA can be modulated independently by the in-
tercalating compound ethidium bromide [76] and by
ATP [77]. The recently observed ethidium bromide
and ATP-dependent modi¢cations in protein-DNA
footprints upstream of ITH1, which could be corre-
lated with changes of the rate of rRNA synthesis but
not of mRNA synthesis, and the indication of a pro-
tein-DNA interaction site upstream of ITH2 have giv-
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en further credence to the model [62]. Nevertheless, it
is di⁄cult to imagine how two initiation events tak-
ing place less than 100 bp apart can determine the
fate of RNA synthesis at the distal end of the 16S
rRNA gene, more than 2500 nucleotides down-
stream.
In addition to the dual H-strand transcription
model, the di¡erence in synthesis rate of rRNA
and mRNA has been explained by an attenuation
event at the border of the 16S rRNA and
tRNALeuUUR genes (Fig. 1). The ¢rst indication of
early termination of the polycistronic H-strand tran-
script came from structural analysis of the 3P-ends of
16S rRNA molecules which revealed that a large
proportion of the molecules have ragged 3P-termini
that are coded for by the immediately adjacent gene
for tRNALeuUUR [78,79]. This suggests that mature
16S rRNA species are generated by imprecise tran-
script termination at the tRNALeuUUR gene as well
as by accurate endonucleolytic cleavage of the longer
precursor RNA. Later, a crude protein fraction was
isolated from mitochondrial lysates of HeLa cells
which, in DNase I footprinting studies, protected
the region immediately downstream of the mtDNA
region corresponding to in vivo produced 3P-ends of
16S rRNA molecules and promoted speci¢c termina-
tion of transcription [80]. The footprint encompasses
a conserved tridecamer sequence block within the
tRNALeuUUR gene (nucleotide positions 3237^3249
of the human mtDNA; Fig. 1), which has been
shown by in vitro deletion mutagenesis experiments
to be essential and su⁄cient for directing termination
[81].
The factor mediating attenuation of transcription
has been termed mTERF [80] or mtTERM [82] and
is known to induce bending of the DNA helix [83]. In
vitro transcription studies have shown that mtTERM
bound to its mtDNA target site functions bidirec-
tionally and shows an even greater e⁄ciency of ter-
mination in the reverse orientation relative to the
promoter site [84]. Thus, in addition to an attenua-
tion function for H-strand transcription, mtTERM
may halt L-strand transcription at a site where no
L-strand encoded genes are found downstream (see
Fig. 1). Bound mtTERM probably stops elongation
of transcription by constituting a physical barrier,
rather than by a speci¢c interaction with the mito-
chondrial RNA polymerase, because mtTERM also
mediates termination of transcription by heterolo-
gous RNA polymerases [83].
Both Clayton’s and Attardi’s groups have shown
that a polypeptide fraction of a mitochondrial lysate
containing polypeptides with a molecular weight of
around 34 kDa has the ability to produce the speci¢c
DNase I footprint at the termination site associated
with mtTERM function [82,85]. The cDNA of the
predominant polypeptide from this fraction was re-
cently cloned and sequenced [86]. The polypeptide
contains two widely separated basic regions and
three leucine zipper motifs which were shown to be
necessary for its speci¢c DNA-binding capacity [86].
The footprint produced by the recombinant protein
was similar but not identical to that produced by the
34-kDa polypeptide fraction. The recombinant pro-
tein was also shown to be unable to promote tran-
scription termination in an in vitro system [86]. These
observations suggest that an additional component
of the 34-kDa polypeptide fraction is required for
the termination activity. This apparent complexity
of mtTERM is not surprising, given that it should
be able to modulate its activity in response to the
cellular demand for mitochondrial rRNAs, on the
one hand, and for mitochondrial tRNAs and
mRNAs on the other.
Interestingly, a heteroplasmic A to G transition in
the middle of the mtTERM binding site (A3243G) is
frequently found in patients with the mitochondrial
encephalomyopathy MELAS (mitochondrial myopa-
thy, encephalopathy, lactic acidosis and stroke-like
episodes) [87] and in patients with maternally inher-
ited adult onset diabetes [88]. In vitro studies have
shown that this mutation dramatically reduces the
a⁄nity of mtTERM for its binding site and causes
a defect in transcript termination [82,83,89]. In con-
trast, steady-state transcript levels upstream and
downstream of the termination site were not a¡ected
by the A3243G transition in cultured cells [89,90] or
in tissues of patients [49,91,92]. Thus, it seems un-
likely that the in vitro observed defective attenuation
of mitochondrial transcription is of pathological sig-
ni¢cance.
3.3. Processing of primary transcripts
Once the RNA polymerase passes the 16S rRNA/
tRNALeuUUR boundary, H-strand transcription ap-
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pears to be straightforward. As no intron sequences
are present in vertebrate mtDNA and intergenetic
sequences are minimal, processing of the long poly-
cistronic H- and L-strand messengers is thought to
be a relatively simple process, requiring only a few
enzymes. Genes for tRNAs £ank the two rRNA
genes and nearly every protein gene (Fig. 1). This
unique genetic organisation has led to the proposal
that the secondary structure of the tRNA sequences
provide the punctuation marks in the reading of the
mtDNA information [27]. Precise endonucleolytic ex-
cision of the tRNAs from the nascent transcripts will
concomitantly yield correctly processed rRNAs and,
in most cases, correctly processed mRNAs [27,93]. In
those cases in which the mRNA termini cannot be
accounted for by tRNA excision (e.g. the messenger
for subunit I of cytochrome c oxidase [27,93]; Fig.
1), the processing enzyme possibly recognises a sec-
ondary structure which shares critical features with
the typical cloverleaf structures of tRNAs.
Maturation of mitochondrial tRNAs involves
three enzymatic activities which were recently identi-
¢ed by Rossmanith and colleagues [94] in an in vitro
HeLa cell mitochondrial tRNA processing system.
Their experiments showed that cleavage at the
5P-end precedes that at the 3P-end. The endonuclease
responsible for 3P-end cleavage has not been charac-
terised. Cleavage at the 5P-end is performed by a
mitochondrial RNase P (mtRNase P). The enzyme
containing fractions prepared by Rossmanith and
colleagues [94] cut mitochondrial tRNA precursors
at the correct 5P-end, but, unlike the preparations
by others (see, e.g. [95]), do not cleave tRNATyr pre-
cursors of Escherichia coli correctly. This suggests
that previous preparations were contaminated with
a cytosolic isoform of RNase P which is apparently
able to accurately process bacterial tRNA precur-
sors. Yeast mtRNase P has been characterised in de-
tail. The enzyme of Saccharomyces cerevisiae is com-
posed of a nuclear-encoded protein and a mtDNA-
encoded RNA species [96,97]. The RNA moiety of
the ribonucleoprotein complex is AU-rich and forms
the catalytic core of the enzyme. Comparison of
mtRNase P RNA from di¡erent yeast species has
revealed a remarkable variation in size from 490 to
140 nucleotides [98].
Maturation of the excised tRNAs is completed by
addition of the sequence CCA to their 3P-end cata-
lysed by ATP(CTP):tRNA nucleotidyltransferase
[94]. Mitochondrial mRNAs are polyadenylated by
a mitochondrial poly(A) polymerase during or imme-
diately after cleavage [99,100], whereas the 3P-ends of
the two rRNAs are post-transcriptionally modi¢ed
by the addition of only short adenyl stretches [78].
Mitochondrial messengers do not carry upstream
polyadenylation signals as found in nuclear messen-
gers.
4. Mitochondrial protein synthesis
4.1. Mitochondrial ribosomes
Early indications of the prokaryotic origin of mi-
tochondria came from observations, now more than
three decades ago, that the spectrum of antibiotics
inhibiting mitochondrial protein synthesis resembles
that of prokaryotic systems (reviewed in [101]). Sub-
sequent research con¢rmed that nearly all constitu-
ents of the mitochondrial translation machinery are
distinct from their cytosolic counterparts. Unique
features of mitochondrial protein synthesis were ¢rst
studied at the molecular level in mitochondrial ribo-
somes. The mitochondrial ribosomes, or mitoribo-
somes, are located in the matrix of the organelle.
Steady-state rRNA levels in rat hepatocytes [102]
suggest that there are 6 100 mitoribosomes per mi-
tochondrion. The physical and chemical properties of
mitoribosomes di¡er considerably from their cyto-
solic as well as their bacterial counterparts. Mamma-
lian mitoribosomes have an unusually low RNA con-
tent and, consequently, a low sedimentation
coe⁄cient of V55S [103^106]. The V39S and
V28S ribosomal subunits contain respectively the
16S and 12S rRNA species encoded by the mtDNA
[103,104]. A 5S rRNA species, typically present in
ribosomes, appears to be absent in mammalian mi-
toribosomes [103,104] but a 23-bp region at the
3P-end of the human 16S rRNA exhibits a 68% se-
quence identity to a portion of the Bacillus subtilis 5S
rRNA. The structural similarity of the region and
its mapping position have led to the suggestion
that this piece represents a truncated 5S rRNA
which remained part of the large rRNA component
[107].
The low RNA content of mammalian mitoribo-
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somes is compensated by a relatively high protein
content and results in a total mass of mitoribosomes
similar to that of bacterial ribosomes. Two-dimen-
sional gel electrophoresis has allowed the resolution
of 85 mitoribosomal protein spots from beef [108]
and 86 from rat [106], however, the actual number
of distinct mitoribosomal proteins may be lower as
di¡erences in staining intensity of some spots suggest
possible proteolytic degradation and contamination
with other proteins cannot fully be excluded. One
can speculate that some mitoribosomal proteins
have adopted structural and functional roles of the
lost rRNA but experimental data as to the functions
of mammalian mitoribosomal proteins are not
available and most recent progress on the elucidation
of the properties of the individual mitoribosomal
proteins comes from studies in S. cerevisiae [109].
4.2. Initiation and elongation of translation
Although isolated intact mitochondria faithfully
carry out protein synthesis, an in vitro mitochondrial
translation system using only mitochondrial extracts
is not available. Due to this persistent lack, many
details of the mitochondrial protein biosynthesis are
poorly understood and only a limited number of the
mammalian auxiliary factors involved in initiation
and elongation of translation have been character-
ised. Termination of the translation process has not
yet been explored.
The mitochondrial translational apparatus is
unique in many ways. As mentioned earlier, the
rRNA and tRNA species are surprisingly small.
The start of the translation process is intriguing be-
cause mammalian mitochondrial mRNAs have no
upstream leader sequences to facilitate ribosome
binding, unlike prokaryotic and eukaryotic cytosolic
messengers, but start at or very near the 5P-end with
the codon for the initiating N-formylmethionine [93].
In addition, the 5P-termini of mitochondrial mRNAs
lack a 7-methylguanylate cap structure [110]. This
excludes a cap recognition and scanning mechanism
for directing the ribosome to the initiation codon as
observed in the cytosol of eukaryotic cells. The low
translational e⁄ciency of mitochondrial messengers
[102] may in fact be the result of the absence of a
5P-end ribosome recognition site and necessitate the
observed abundance of mitochondrial messengers
[111,112] to ensure that a su⁄cient level of transla-
tion occurs.
In vitro experiments with bovine mitoribosomes
have indicated that the small (28S) ribosomal subunit
has the ability to bind mRNA tightly in a sequence-
independent manner and in the apparent absence of
auxiliary initiation factors or initiator tRNA [113],
unlike prokaryotic [114] and eukaryotic cytosolic
[115] systems. Judging from the size of the RNA
fragments protected from RNase T1 digestion, the
major interaction between the small subunit and
the messenger occurs over a 30^80-nucleotide stretch,
but V400 nucleotides are minimally required for ef-
¢cient binding [113,116,117]. This may explain why
the two shortest expressed open reading frames of
mammalian mtDNA (ATPase8 and ND4L ; 6 300
bp) are both part of overlapping genes (ATPase8/
ATPase6 and ND4L/ND4 ; see Fig. 1). Both pairs
of genes result in dicistronic messengers [100]. Mono-
cistronic transcripts of the ATPase8 and ND4L genes
are possibly too short to interact e¡ectively with the
small subunit.
After binding of the small ribosomal subunit to
the messenger, the subunit is assumed to move to
the 5P-end of the mRNA mediated by yet unspeci¢ed
auxiliary initiation factors [116,118]. The only initia-
tion factor identi¢ed in mammalian mitochondria to
date is mtIF-2 [118,119]. The cDNAs for bovine as
well as human mtIF-2 have been cloned and se-
quenced [120,121]. The human factor shows 36%
amino acid identity with E. coli IF-2. This mono-
meric protein factor belongs to the family of
GTPases and promotes fMet-tRNA binding to the
small ribosomal subunit in the presence of GTP
and a template, reminiscent of the bacterial factor
IF-2. Detailed in vitro characterisation of bovine
mtIF-2 [119,122] has indicated that mtIF-2 may
bind to the small ribosomal subunit prior to its in-
teraction with GTP, however, GTP enhances the af-
¢nity between mtIF-2 and the small subunit and al-
lows fMet-tRNA to join the complex. Hydrolysis of
GTP is thought to facilitate the release of mtIF-2
and the concomitant association of the large (39S)
ribosomal subunit to form the 55S initiation com-
plex. Nonhydrolysable analogues of GTP can still
promote formation of the initiation complex, indicat-
ing that GTP hydrolysis is not strictly required for
subunit joining [119].
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Three mitochondrial elongation factors, mtEF-Tu,
mtEF-Ts and mtEF-G, have been puri¢ed from bo-
vine liver [123,124]. The cDNAs for all three factors
have been cloned and sequenced from mammalian
sources [125^129] and the gene for human mtEF-
Tu has been mapped to chromosome 16q11.2 [129].
The in vitro characterisation of the puri¢ed factors
and the cDNA sequence information have revealed
striking similarities with the corresponding prokary-
otic factors. Consequently, elongation of the nascent
mitochondrial polypeptide is assumed to proceed in a
similar fashion as in E. coli [130]. Di¡erent from E.
coli EF-Tu and EF-Ts, mammalian mtEF-Tu and
mtEF-Ts form a tightly associated complex that, un-
like the bacterial complex, cannot readily be dissoci-
ated by guanidine nucleotides alone [123]. However,
it was recently demonstrated that the mtEF-Tu-Ts
complex will dissociate in the presence of GTP and
charged tRNAs [131].
4.3. The e¡ect of tRNA point mutations on mtDNA
expression
Pathogenic mutations in mitochondrial genes are
generally heteroplasmic, i.e. wild-type and mutant
mtDNA co-exist in the same cell. The wild-type
mtDNA allows the mutant mtDNA with the other-
wise lethal base change to persist. Maternally inher-
ited, mitochondrial encephalomyopathies are often
associated with point mutations in mitochondrial
tRNA genes [132]. Muscle biopsies from patients
show focal histochemical defects of cytochrome c
oxidase associated with a non-random distribution
of mutant and wild-type mtDNA [49,91]. This mo-
saic expression of the disease is also observed in pri-
mary cell cultures of these patients as illustrated in
Fig. 3.
Recent progress on how mitochondrial tRNA mu-
tations exert their e¡ect has largely come from ex-
periments in which patients’ mtDNA has been trans-
ferred to b0 control cells. These studies unequivocally
demonstrated that tRNA point mutations, like the
A3243G transition found in the tRNALeuUUR gene
of MELAS patients and the A8344G transition in
the tRNALys gene commonly associated with
MERRF (myoclonic epilepsy with ragged-red ¢bres)
[134], are alone su⁄cient to impair intramitochon-
drial protein synthesis [89,90,135]. These and other
cell culture studies [136] have revealed a steep thresh-
old e¡ect: mitochondrial translation remains unaf-
fected by tRNA point mutations until s 85% of
the mtDNA molecules are mutated.
Di¡erent mechanisms can account for the ob-
served impairment of protein synthesis. Apart from
a potential e¡ect on transcription termination, the
tRNALeuUUR A3243G transition appears to a¡ect
the processing of primary mitochondrial transcripts
[90,92]. Cybrids resulting from re-population experi-
ments of a human b0 cell line with mtDNA carrying
the A3243G transition showed a small (less than 2-
fold) but consistent increase in the steady-state levels
of a partially processed RNA species derived from
Fig. 3. Comparison of the expression of the mtDNA-encoded subunit I of cytochrome c oxidase in a control ¢broblast culture (A)
with that in a ¢broblast culture from a patient with MELAS (B). More than 95% of the patient’s mtDNA molecules harboured the
tRNALeuUUR A3243G mutation. The presence of subunit I was visualised with £uorescein isothiocyanate (FITC)-labelled antibodies
(green £uorescence), while the cell nuclei were counter-stained with 4,6-diamidino-2-phenylindole (DAPI; blue £uorescence) [133]. A
patient’s cell not expressing subunit I is indicated with an arrow.
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transcription of the 16S rRNA+tRNALeuUUR+ND1
genes [90,137], which are contiguous in the mtDNA
(Fig. 1). Steady-state levels of mature 16S rRNA,
tRNALeuUUR and ND1 mRNA are not a¡ected by
the mutation [90,137]. Although the steady-state level
of the immature transcript is extremely low in the
cybrids compared to the level of mature 16S
rRNA, the level showed a strong inverse correlation
with the rates of oxygen consumption of the cybrids
(an indicator of mitochondrial oxidative phosphoryl-
ation capacity [138,139]). These observations have
led to the hypothesis [90,138] that the unprocessed
transcript, which contains 16S rRNA, is incorpo-
rated into ribosomes rendering them functionally de-
¢cient. If this results in stalling of the translation of
polyribosomal mRNAs, then a small increase of un-
processed transcript could interfere disproportionally
with mitochondrial translation and explain the severe
oxidative phosphorylation defects observed in the
patients.
Alternatively, point mutations in tRNA genes may
induce a conformational change of the tRNA result-
ing in a decreased stability of the molecule. A change
in structure may also a¡ect the identi¢cation by the
cognate aminoacyl-tRNA synthase and lead to de-
creased levels of aminoacylation or even mischarging
of mutated tRNAs. In prokaryotes, the T8C region
of the tRNA molecule is important for recognition
and binding by EF-Tu and ribosomes, therefore, mu-
tations in the T8C region of mitochondrial tRNAs
are likely to a¡ect their a⁄nity with mtEF-Tu and
mitoribosomes. High resolution Northern (RNA)
blot hybridisation experiments have indicated that
these mechanisms are indeed likely to play a role in
the aetiology of these diseases. In cell lines carrying
either tRNALys A8344G [140,141], tRNALeuUUR
C3256T [142], or tRNAAsn G5703A mutations
[143], markedly reduced steady-state levels of the af-
fected tRNA have been found, suggesting an in-
creased susceptibility to nucleolytic digestion. More-
over, a V40% reduction in aminoacylation of
tRNALys has been demonstrated in cell lines with
the tRNALys A8344G mutation [141]. In contrast,
cell lines with the tRNALys C8356T mutation exhib-
ited no signi¢cant decrease in tRNALys content [140]
but this mutation, which is located in the T8C arm
of the molecule, may interfere with the binding of
mtEF-Tu or the mitoribosome [144].
5. Replication of mtDNA
5.1. Basic mechanism of mammalian mtDNA
replication
The fortuitously slow rate of mtDNA replication
has facilitated the isolation and characterisation of in
vivo replicative intermediates and has provided the
now generally accepted model of the replication cycle
of mammalian mtDNA. Early studies, which pre-
dominantly relied on electron microscopic and cen-
trifugal analysis of mtDNA molecules from cultured
cells, indicated that mammalian mtDNA molecules
replicated unidirectionally from two spatially and
temporally distinct, strand-speci¢c origins [23]. The
origin of H-strand replication (OH) is located down-
stream of the LSP in the D-loop region of the ge-
nome, whereas the origin of L-strand replication
(OL) is at two-thirds of the genomic distance away
from OH with respect to the polarity of H-strand
synthesis (Fig. 1). A round of replication begins at
OH with the synthesis of a daughter H-strand and
continues along the parental L-strand to produce a
full H-strand circle. Only after the replication fork
has passed the second replication origin, OL, is syn-
thesis of the L-strand initiated which proceeds in a
direction opposite to that of H-strand replication
(reviewed in [145]).
5.2. Initiation of H-strand synthesis
Fine mapping of RNA and DNA species in the D-
loop region of human and mouse mtDNA have sug-
gested that short mitochondrial transcripts, originat-
ing at ITL, serve as primers for the initiation of syn-
thesis of nascent H-strands (Fig. 2; [146,147]). Thus,
replication of mammalian mtDNA appears to be in-
timately linked with mitochondrial transcription.
There are no known di¡erences between the initia-
tion of L-strand transcription and the initiation of
RNA primer formation for mtDNA replication [36]
and it is not clear which mechanism decides between
transcript elongation or H-strand synthesis. Transi-
tions from RNA to DNA synthesis take place at
several distinct sites that collectively constitute OH
in a region of three short, evolutionary conserved
sequence blocks, named CSB I, II and III (Fig. 2;
[34]).
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As the precursor RNA primer extends beyond the
transition sites of RNA to DNA synthesis, the pri-
mary transcript is believed to be enzymatically proc-
essed to yield the mature primer RNA 3P-termini.
Because of their location, it has been speculated
that CSB I, II and III direct the precise cleavage of
primary transcripts to provide the appropriate pri-
mer species [36]. Recent in vitro transcription studies
of the OH region with mitochondrial RNA polymer-
ase fractions [148] indicated that the precursor RNA
primer exists as a stable and persistent RNA-DNA
hybrid also known as an R-loop. Hybrid formation
requires the CSB II element and is also a¡ected by
mutations in CSB III.
The search by Clayton’s group for catalytic activ-
ity capable of processing L-strand transcripts con-
taining OH sequences led to identi¢cation of the en-
zyme called mitochondrial RNA processing
endonuclease (RNase MRP; reviewed in [149]). In
their initial studies, in which single-stranded OH-con-
taining RNA species were used as substrate, the in
vitro RNase MRP cleavage sites did not match with
all in vivo 5P-ends of the nascent human and mouse
H-strands (cf. [146,147,150,151]). However, recently
Lee and Clayton [152] demonstrated that mouse
RNase MRP does cleave the precursor RNA in the
context of a triple-stranded R-loop con¢guration in
vitro at the majority of the 3P priming sites found in
vivo.
RNase MRP is a ribonucleoprotein [149]. The
bulk of the enzyme is present in the nucleolus where
it plays a direct role in processing of precursor 5.8S
rRNA [153^155]. The predominant nucleolar loca-
tion of the enzyme has led to controversy as to its
mitochondrial function [156,157]. However, recent
ultrastructural in situ hybridisation experiments indi-
cated a preferential localisation of RNase MRP
RNA to nucleoli as well as mitochondria in compar-
ison to the nucleoplasm and cytosol [158], consistent
with a dual role of RNase MRP in maturation of
nuclear rRNAs and mitochondrial RNA primers.
Null mutant analysis of the RNase MRP RNA
gene in S. cerevisiae indicated that the gene is essen-
tial for cellular viability [159], agreeing with the nu-
clear function of the factor. Genetic evidence linking
RNase MRP to mitochondrial biogenesis was re-
cently provided by a strain of Schizosaccharomyces
pombe with a functional dominant mutation in its
RNase MRP RNA gene. The strain was shown to
require the mitochondrially associated, nuclear mu-
tation ptp-1 for viability [160].
Another nuclease implicated in processing of pre-
cursor RNA primers for H-strand replication is en-
donuclease G [161]. The enzyme was ¢rst isolated
from bovine heart mitochondria as a homodimer of
a V29 kDa polypeptide [162] and cDNA sequences
specifying endonuclease G of several mammalian
species, including human, were recently reported
[163]. The mitochondrial location of endonuclease
G is undisputed but the enzyme is also found in
the nucleus [161,164]. Endonuclease G has a rather
wide spectrum of nucleolytic activities: it cleaves
GC-rich double-stranded and single-stranded DNA
tracts, RNA and an RNA-DNA heteroduplex con-
taining the mouse OH [161]. The in vitro RNA cleav-
age sites of the heteroduplex, however, do not align
with all predicted in vivo priming sites. Deletion of
the homologous gene in S. cerevisiae does not seem
to a¡ect mtDNA metabolism [165]. Thus, any con-
clusion as to the function of endonuclease G in mi-
tochondrial biogenesis appears premature.
In vertebrates, most H-strand synthesis events stall
shortly after initiation. Arrested nascent H-strands
remain annealed to their template L-strand and cre-
ate the triplex D-loop structure [145]. The 3P-ends of
prematurely terminated H-strands map V50 nucleo-
tides downstream of a short (15 bp) conserved se-
quence element, called the termination-associated se-
quence (TAS [149]). The number of TAS elements
and H-strand termination sites vary per species.
The human mitochondrial genome contains only a
single TAS element and there is only one major H-
strand termination site, with two minor termination
sites mapping immediately adjacent to the major site
[166]. The mechanism which determines whether a
nascent H-strand ends downstream of the TAS ele-
ment or elongates over the entire length of the ge-
nome is not known but is likely to be a key regulator
of the mtDNA copy number in a cell. Recently, in
vivo and in organello footprinting studies indicated
multiple protein binding sites in the TAS region of
human and rat mtDNA [167]. Furthermore, a 48-
kDa protein has been isolated from bovine mito-
chondria with a TAS-speci¢c DNA binding activity
[168]. These data suggest that nuclear-encoded trans-
acting proteins interact with the cis-acting TAS ele-
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ments and regulate the equilibrium between D-loop
formation and H-strand replication.
5.3. Initiation of L-strand synthesis
The replication origin OL was ¢rst identi¢ed in
mouse and later in human mtDNA by 5P-end map-
ping of in vivo nascent L-strands [169,170]. The ori-
gin is located in a non-coding region of V30 nucleo-
tides and is £anked by ¢ve tRNA genes (Fig. 1). OL
is only activated when the parental H-strand is dis-
placed as a single strand by the growing daughter H-
strand. After strand displacement, OL is thought to
adopt a distinctive stem-loop structure [36]. In vitro
run-o¡ replication studies of OL have suggested that
this con¢guration serves as the recognition structure
for a mitochondrial DNA primase which provides a
short RNA primer for L-strand synthesis [171,172].
However, the location of OL within a cluster of
tRNA genes and the fact that the potential stem-
loop structure might be absent in mtDNA of some
vertebrate species [149] suggest that additional sec-
ondary structures contribute to DNA primase
recognition in vivo.
RNA priming starts at the T-rich portion of the
predicted OL-loop and the transition from RNA to
DNA synthesis takes place at a speci¢c site near a
critical GC-rich element at the base of the hairpin
[171,172]. The mitochondrial DNA primase involved
in priming of the L-strand synthesis has only been
partly puri¢ed [173]. The physical properties of the
mitochondrial enzyme are distinct from the major
nuclear DNA primase. Mitochondrial DNA primase
is associated with RNA. Treatment with ribonuclease
A leads to rapid inactivation of primase activity and
suggests a crucial role for the associated RNA.
The predominant RNA moiety co-fractioning with
primase activity is the nuclear gene product 5.8S
rRNA [173]. However, as only crude fractions of
mitochondrial DNA primase have been analysed,
the co-fractionation of 5.8S rRNA might have been
the result of an adventitious contamination.
5.4. Trans-acting factors involved in elongation and
maturation of progeny strands
DNA polymerase Q is the only DNA polymerase
present in mitochondria [174]. Disruption of the
DNA polymerase Q gene in S. cerevisiae has demon-
strated that the enzyme is necessary for mtDNA syn-
thesis but has no basic function outside the organelle
[175]. DNA polymerase Q accounts for only a small
fraction of the total cellular DNA polymerase activ-
ity, yet its unique enzymatic properties, its resistance
to aphidicolin and its sensitivity to dideoxynucleoside
triphosphates make it relatively easy to identify the
mitochondrial DNA polymerase [176]. The enzyme
has been isolated from humans [177] and several
other organisms (reviewed in [149]). DNA polymer-
ase Q appears to be prone to proteolytic degradation
and its subunit structure is still a matter of debate.
Most recent data suggest that the enzyme is a heter-
odimer in vertebrates comprised of a 125^140-kDa
polypeptide and a 35^54-kDa polypeptide (see, e.g.
[178]). In addition to its 5PC3P polymerase activity,
DNA polymerase Q has an intrinsic 3PC5P exonu-
clease activity which is highly mispair-speci¢c and
ensures faithful replication of mtDNA [176]. In re-
cent years, cDNA sequences specifying the major
subunit have been identi¢ed from a number of verte-
brate species, including human [179^181]. Sequence
comparisons with the polypeptide from S. cerevisiae
have shown that the major subunit is evolutionarily
conserved and have allowed identi¢cation of both
the polymerase and the exonuclease proof-reading
domain. Recent kinetic studies with the recombi-
nantly expressed, 140-kDa human subunit showed
that the major subunit is a relatively poor polymer-
ase compared to other DNA polymerases, suggesting
that this core subunit may require accessory factors
to increase the enzymatic rate [182]. Nevertheless, the
kinetic parameters indicated that the major subunit
could replicate the mitochondrial genome in a phys-
iologically relevant time frame [182].
Replicative intermediates of mtDNA feature ex-
tensive single-stranded DNA regions [145]. A mito-
chondrial single-stranded binding protein (mtSSB)
has been isolated and cloned from human [183] and
several other species (reviewed in [149]). Mutation
analysis in S. cerevisiae has demonstrated that
mtSSB is required for maintenance of mtDNA
[184]. Binding of mtSSB to the exposed single-
stranded mtDNA is thought to maintain the integrity
of these regions and to stimulate the overall rate of
DNA synthesis by DNA polymerase Q in vivo (see,
e.g. [185,186]). The mitochondrial protein is distinct
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from the nuclear single-stranded binding protein but
resembles the E. coli single-stranded binding protein
in structure as well as in DNA-binding properties
[187,188]. The protein interacts with single-stranded
DNA as a homotetramer [187^189]. The crystal
structure of human mtSSB suggests that single-
stranded DNA wraps around the tetrameric complex
through electropositive channels guided by £exible
loops [189].
Several additional enzymatic activities are consid-
ered to be essential for mtDNA replication but only
a few supplementary enzymes of the mitochondrial
replication machinery have been identi¢ed. Helicases
catalyse the unwinding of duplex DNA by disrupting
the hydrogen bonds that hold the two strands togeth-
er to provide single-stranded templates for DNA pol-
ymerases [190]. An ATP-dependent helicase has been
identi¢ed and partly puri¢ed from mitochondria of
bovine brain [191] and sea urchin eggs [192]. The
enzyme shows biochemical similarities with Rep heli-
case of E. coli and shares its 3PC5P polarity of un-
winding with respect to the single-stranded portion
of the partial duplex DNA. This direction would
place the mitochondrial helicase on the template
strand ahead of DNA polymerase Q during mtDNA
replication.
Type I topoisomerases catalyse the relaxation of
supercoiled DNA, while type II topoisomerases are
responsible for the introduction of supercoils. Topo-
isomerases change the topology of DNA by transi-
ently breaking the backbone bonds, using a mecha-
nism involving either single strand (type I) or double
strand (type II) cleavage [193]. Mitochondrially asso-
ciated, type I topoisomerases have been identi¢ed
from various sources, including human leukemia
cells [194] and human platelets [195]. The mitochon-
drial enzyme is immunologically related to its nuclear
counterpart [196,197] and yeast mitochondrially as-
sociated type I topoisomerase activity is abolished
when the gene that encodes the nuclear type I top-
oisomerase is disrupted [198]. Despite the apparent
immunological and genetic relationship between the
nuclear and mitochondrial type I topoisomerases, the
enzymes can be distinguished from each another by a
di¡erential response to chemical reagents and inhib-
itors, both in yeast and humans [195,197].
Mitochondrially associated type II topoisomerases
have been identi¢ed in Dictyostelium discoideum
[199], rat liver [200] and human leukemia cells
[194]. Further support for the existence of a distinct
mitochondrial type II topoisomerase comes from
¢ndings with cell cultures grown in the presence of
cipro£oxacin. This antibiotic inhibits prokaryotic
type II topoisomerases much more than the eukary-
otic nuclear enzyme. Treatment of cultured cells with
cipro£oxacin causes double-stranded breaks in
mtDNA and results in loss of the mitochondrial ge-
nome [201]. These observations suggest the presence
of a bacterial-like type II topoisomerase in mitochon-
dria.
5.5. A role for mtTFA in mtDNA maintenance
In addition to its role in transcription and, conse-
quently, primer formation for H-strand synthesis,
mtTFA appears to have a function in maintenance
of mtDNA. Mitochondria do not contain histones
[202,203]. Yeast mtTFA [204] contains a tandem of
HMG DNA-binding motifs, similar to mtTFA of
vertebrates, but yeast mtTFA lacks the basic C-ter-
minal region shown to be important for promoter
selection in vertebrates [60]. The yeast homologue
is not considered to play a key role in initiation of
transcription [37] but is thought to have a histone-
like function in coating the entire mitochondrial ge-
nome [66,202]. Likewise, binding of vertebrate
mtTFA is not restricted to the regions upstream of
the HSP and LSP. The factor is inherently £exible in
its recognition of DNA sequences [52,65,71] and a
comparative in organello and in vitro footprinting
study indicated that human mtTFA binds at regu-
larly spaced intervals throughout a 500-bp region
encompassing OH and the two major promoters
[61]. Binding is largely excluded from CSB II and
III but mtTFA shows a strong interaction with
CSB I [61,65]. As some of the intervals of mtTFA
binding align with prominent 5P-ends of nascent H-
strands, it has been suggested that the phased bind-
ing of the protein functionally organises the D-loop
and facilitates access of other trans-acting factors in-
volved in the transition from RNA to DNA synthesis
[37,61,65].
There exists a direct correlation between mtTFA
and mtDNA steady-state levels. Heterozygous
mtTFA knockout mice exhibit reduced mtDNA
copy numbers and homozygous knockout embryos
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lack mtDNA and die [205]. This demonstrates the
importance of mtTFA in maintaining mtDNA levels
in vivo. Conversely, in b0 cell cultures mtTFA levels
are low [206^208], while in patients with mitochon-
drial myopathies increased levels of mtTFA are
found in ragged-red muscle ¢bres with accumulated
levels of mtDNA [206]. Although mtTFA protein
levels are low in b0 cells, mtTFA mRNA levels are
normal [206,207], indicating that mtTFA protein lev-
els are post-transcriptionally regulated by mtDNA
levels. Possibly, binding to mtDNA protects mtTFA
from proteolytic degradation. Similarly, mtSSB pro-
tein levels appear to correlate with mtDNA content
but the expression of mtSSB is at least in part regu-
lated at the level of transcription [209]. On the other
hand, DNA polymerase Q is constitutively expressed
[209]; even in b0 cells, the steady-state level of the
polymerase protein is una¡ected [208].
Interestingly, the expression of mtTFA is reduced
during mammalian spermatogenesis, most likely due
to the production of alternate, testis-speci¢c mtTFA
transcript isoforms [210,211]. The low mtDNA copy
number observed in sperm cells may, therefore, be a
direct result of a decreased expression of mtTFA
which, together with other mechanisms, may prevent
paternal transmission of mtDNA [211].
6. Prospects
Transcription, translation and replication of
mtDNA are controlled by many factors. Cis-acting
mtDNA sequences have been identi¢ed in mapping
studies and by mutation analysis. Characterisation of
trans-acting factors proved more di⁄cult because of
their low cellular concentration and the potential risk
of contamination with analogous enzyme activities of
nuclear or cytosolic origin in cell fractionation ex-
periments. Still, some relatively abundant mitochon-
drial enzymes could be puri¢ed to homogeneity and
their human coding sequences have been cloned uti-
lising conventional molecular biological techniques.
More recently, problems with puri¢cation have
been circumvented by screening of human EST data-
bases with sequences of yeast genes involved in tran-
scription and replication [51]. As a result, several key
enzymes involved in transcription and replication of
human mtDNA have now been cloned and mapped
to chromosomes (Table 1). Nevertheless, comple-
mentary strategies are needed to characterise the
full repertoire of enzymes involved in mtDNA ex-
pression as evolutionary divergence between factors
may prevent successful cyberscreening and certain
factors could be unique to the mammalian mitochon-
drial system.
Patients with inborn errors of mitochondrial rep-
lication, transcription or protein synthesis present a
challenge as well as a resource to the biochemist. The
challenge is to understand the molecular mechanism
of the disease, whereas the resource is as a naturally
occurring mutant which provides an opportunity to
characterise aspects of these processes in humans
that are di⁄cult to study by other means. Patients
with mtDNA mutations are providing unparalleled
insights into the roles of cis-acting elements. With
respect to trans-acting factors involved in mainte-
nance and replication of mtDNA, one group of pa-
tients has attracted special attention. In 1991, Mor-
aes and colleagues [216] described several infants
with marked depletion of mtDNA and defective ox-
idative phosphorylation. Since its discovery, more
than 30 patients have been described with this syn-
drome (discussed in [217]). Most patients present
soon after birth with muscle weakness and hepatic
failure or renal tubulopathy associated with a severe
depletion of mtDNA (88^99%) in a¡ected tissues at
Table 1
Chromosomal location of putative human trans-acting factors involved in mitochondrial transcription and replication
Factor Gene Chromosome
Endonuclease G ENDOG 9q34.1 [57]
DNA polymerase Q POLG 15q24-q26 [180,212,213]
Mitochondrial processing endoribonuclease (RNase MRP) RNA RMRP 9p21-p12 [214,215]
Mitochondrial RNA polymerase POLMRT 19p13.3 [51]
Mitochondrial single-stranded binding protein (mtSSB) SSBP 7q34 [57,183]
Mitochondrial transcription factor A (mtTFA) TFAM (TCF6) 10q21 [54,57]
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post-mortem. No mtDNA mutations have been
documented in these infants and pedigree analysis
is consistent with autosomal inheritance of the trait.
A nuclear genomic involvement has been con¢rmed
in two families by mtDNA transfer techniques
[218,133]. The progressive loss of mtDNA in tissues
is also observed in cell cultures of some of the pa-
tients [218,133]. In the depleting cultures, a fraction
of the cells still contains apparently normal levels of
mtDNA but mtDNA replication is more or less di-
minished in all cells (Fig. 4). Taken together, these
observations strongly suggest a replication arrest due
to a de¢ciency of a trans-acting, nuclear-encoded fac-
tor.
Patients with mtDNA depletion display decreased
levels of mtTFA in tissue [206,207]. However, the
fact that remnant mtDNA is still transcribed in cell
cultures of the patients [133,219] suggests that the
decrease in mtTFA levels is probably secondary to
depletion of mtDNA. Other candidate genes, listed
in Table 1, are currently being evaluated but, to date,
no molecular defects underlying the mtDNA deple-
tion have been reported. A de¢ciency of one of the
key enzymes of mtDNA replication is likely to be
lethal early in embryonic development [205]. The ap-
parent tissue-speci¢c and neonatal expression of
symptoms indicates a less drastic defect and points
to the de¢ciency of a factor involved in regulation of
mtDNA copy numbers. Regulatory factors are gen-
erally present at very low cellular concentrations and
only at certain stages of development, making it ex-
ceedingly di⁄cult to characterise these factors by tra-
Fig. 4. Comparison of total mtDNA (A, B) and recently replicated mtDNA (C, D) levels in a control myoblasts culture (A, C) with
that in a myoblast culture from a patient exhibiting mtDNA depletion (B, D). In (A) and (B), SYTO 17 (Molecular Probes) was used
to visualise mtDNA; this cell-permeant, red £uorescent dye reveals the characteristic mitochondrial structures in the cell if mtDNA is
present. In (C) and (D) replicating mtDNA was visualised by the incorporation of 5-bromo-2P-deoxyuridine (BrdU) and subsequent
detection with an FITC-labelled antibody (green £uorescence). Nuclei were stained £uorescent blue with DAPI. Cells were either cul-
tured for 1.5 h in medium containing 2 Wg/ml of DAPI, followed by culturing for 30 min in 62.5 nmol of SYTO 17, 2 Wg/ml of
DAPI, 10 mM of HEPESWNaOH (pH 7.4), 150 mM of NaCl, 2 mM of CaCl2 and 2 mM of MgCl2 (A, B), or cells were cultured for
16 h in medium containing 15 WM of BrdU, 10 Wg/ml of aphidicolin followed by immunological detection of BrdU (Detection kit I,
Boehringer Mannheim) and counter staining with DAPI (C, D). Arrows indicate a patient’s cell lacking mtDNA or a patient’s cell de-
void of mtDNA replication.
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ditional means. It may, however, be feasible to iden-
tify the de¢cient factor in complementation studies of
mtDNA depleting cell cultures with a human cDNA
expression library. This approach is facilitated by the
fact that the patient’s cells, because of impairment of
the oxidative phosphorylation complexes, become
auxotrophic for uridine and pyruvate [218,133],
which provides selectable markers to identify com-
plementing cDNAs.
One can anticipate that future progress in the ¢eld
of replication, transcription and translation of hu-
man mtDNA will increasingly come from detailed
case studies as exempli¢ed above for mtDNA deple-
tion. This research will not only enrich science but
will also permit the development of diagnostic tools
as well as new pathogenic insights to minimise the
devastating consequences of a defective expression of
the mitochondrial genome.
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